SOPHiA GENETICS is excited to be part of the 8th Annual Liquid Biopsy for Precision Oncology Summit, held in person in San Diego, CA, USA, from February 28 to March 1, 2024.
You will have the chance to chat with our experts and learn more about our collaboration with AstraZeneca and Memorial Sloan Kettering Cancer Center (MSK) to decentralize their MSK-ACCESS® assay.
TALK
Access to Precision Oncology with Decentralized Liquid Biopsy Solutions
Talk, February 29
12-12:30 PM
Track B: Clinical Development & Commercialization
Liquid biopsy is emerging as a revolutionary technology, holding promise for swift and precise diagnostics. Despite the potential to positively impact precision oncology and the increasing popularity of NGS-based assays, liquid biopsy faces challenges, including workflow standardization across the globe, regulatory issues, guideline inclusion, and reimbursement hurdles.
Join us in this talk to hear about the SOPHiA GENETICS’ journey in expanding access to Liquid Biopsy at a global scale.
- Understand the vital role of decentralizing liquid biopsy testing for early detection, patient identification, and treatment monitoring
- Learn about SOPHiA DDM™ Liquid Biopsy (LBx) Solutions and the power of our decentralized and technology-agnostic SOPHiA DDM™ Platform
- Hear about SOPHiA GENETICS’ collaboration with MSK and AstraZeneca, aiming to expand global access to advanced cancer testing and accessibility through MSK- ACCESS® powered by the SOPHiA DDM™ Platform
Learn more about our collaboration with AstraZeneca and MSK 
Presented by
T. Scott Reid, PhD
VP & Global Head of Diagnostics
SOPHiA GENETICS
